Ad
Monday, 16 December 2019
Britain's GSK seeks U.S approval for rival to J&J's multiple myeloma drug
GlaxoSmithKline said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson and Genmab's Darzalex.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment